Efficacy and Safety of Subcutaneous Belimumab in Anti-Double-Stranded DNA-Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus.

Doria, A

Efficacy and Safety of Subcutaneous Belimumab in Anti-Double-Stranded DNA-Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus. [electronic resource] - Arthritis & rheumatology (Hoboken, N.J.) 08 2018 - 1256-1264 p. digital

Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

2326-5205

10.1002/art.40511 doi


Adult
Antibodies, Antinuclear--blood
Antibodies, Monoclonal, Humanized--administration & dosage
Complement C3--deficiency
DNA--immunology
Double-Blind Method
Female
Humans
Injections, Subcutaneous
Intention to Treat Analysis
Lupus Erythematosus, Systemic--blood
Male
Severity of Illness Index
Treatment Outcome